Placental-derived stem cells: Culture, differentiation and challenges

Maira S Oliveira, João B Barreto-Filho

Maira S Oliveira, João B Barreto-Filho, College of Veterinary Medicine, Veterinary School, Universidade Federal de Minas Gerais, Belo Horizonte, MG 30161-970, Brazil
Maira S Oliveira, João B Barreto-Filho, Department of Veterinary Medicine, Universidade Federal de Lavras, Lavras, MG 37200-000, Brazil

Author contributions: Oliveira MS and Barreto-Filho JB both contributed to this paper.

Supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do estado de Minas Gerais (FAPEMIG).

Conflict-of-interest: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Maira S Oliveira, VMD, MSc, PhD, College of Veterinary Medicine, Veterinary School, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, Caixa Postal 567, Belo Horizonte, MG 30161-970, Brazil. maira_oliveira@yahoo.com

Received: October 13, 2014
Peer-review started: October 14, 2014
First decision: November 27, 2014
Revised: March 17, 2015
Accepted: April 10, 2015
Published online: May 26, 2015

Abstract

Stem cell therapy is a promising approach to clinical healing in several diseases. A great variety of tissues (bone marrow, adipose tissue, and placenta) are potentially sources of stem cells. Placenta-derived stem cells (p-SCs) are in between embryonic and mesenchymal stem cells, sharing characteristics with both, such as non-carcinogenic status and property to differentiate in all embryonic germ layers. Moreover, their use is not ethically restricted as fetal membranes are considered medical waste after birth. In this context, the present review will be focused on the biological properties, culture and potential cell therapy uses of placental-derived stem cells. Immunophenotype characterization, mainly for surface marker expression, and basic principles of p-SC isolation and culture (mechanical separation or enzymatic digestion of the tissues, the most used culture media, cell plating conditions) will be presented. In addition, some preclinical studies that were performed in different medical areas will be cited, focusing on neurological, liver, pancreatic, heart, muscle, pulmonary, and bone diseases and also in tissue engineering field. Finally, some challenges for stem cell therapy applications will be highlighted. The understanding of the mechanisms involved in the p-SCs differentiation and the achievement of pure cell populations (after differentiation) are key points that must be clarified before bringing the preclinical studies, performed at the bench, to the medical practice.

Key words: Fetal membrane; Placenta; Embryonic stem cells; Mesenchymal stem cells; Cell therapy

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Fetal membranes are a source of stem cells, namely placenta-derived stem cells (p-SCs), which are in between embryonic and mesenchymal stem cells sharing characteristics with both, such as the capacity to differentiate in all germ layers and the dearth of tumorgenicity. Many preclinical studies have been investigated the potential of p-SC use in different medical areas, such as neurology, cardiology,
orthopedics, gastroenterology, and tissue engineering, showing promising results, but also some drawbacks. The present review will focus on different aspects of biological properties and potential clinical uses of p-SCs.

Oliveira MS, Barreto-Filho JB. Placental-derived stem cells: Culture, differentiation and challenges. World J Stem Cells 2015; 7(4): 769-775 Available from: URL: http://www.wjgnet.com/1948-0210/full/v7/i4/769.htm DOI: http://dx.doi.org/10.4252/wjsc.v7.i4.769

INTRODUCTION

Stem cell therapy is a promising approach to clinical healing in several diseases. Neurology[1], orthopedics[2] and cardiology[3] are just a few medical branches in which the benefits of stem cell therapy have been mentioned. The prolific capacity of stem cells (either embryonic or mesenchymal), taken together with the ability to generate different cell lineages and its self-renewal properties are the major features of these cells that allow their use and manipulation in biology and medicine[4,5]. A great variety of tissues (bone marrow, adipose tissue, and endometrium) are potentially sources of stem cells and among them the placenta is a transient organ from which it is possible to obtain mesenchymal stem cells[5].

The term placenta constitutes a very reliable rich source of fetal mesenchymal stem cells[6-9]. These cells are capable of differentiating into multiple different cell types and have immunological properties that suggest their use in an allogenic transplantation setting[10-12].

In this respect, it is important to remember that placenta has a fundamental role in maintaining fetomaternal tolerance and, therefore, the immunomodulatory properties of these cells have been investigated with the aim of exploring their applicability in cell therapy-based treatments[11-13]. Their recovery does not involve any invasive procedures for the donor and their use does not create any ethical issue. In addition, the fact that placenta is generally discarded after birth as medical waste and is available in large supplies, makes placental-derived stem cells (p-SCs) excellent candidates for cell therapy. The current review is focused on the biological properties, culture and potential cell therapy applications of p-SCs.

P-SC

Biological properties

Animal development is initiated by fertilization of the egg with sperm, which is immediately followed by mitotic cell divisions, or cleavages, to generate blastomeres. For eutherians, such as the mouse and human, the first cell differentiation event is the establishment of two distinct cell lineages: the trophectoderm (TE) and the inner cell mass (ICM)[14]. TE engages in implantation by directly interacting with the mother’s uterus, and gives rise to tissues in the placenta. It is only after implantation that the three germ layers form from the ICM, which ultimately generates all the tissues in the animal body[14]. Pluripotency is a characteristic of the ICM and is related to the expression of octamer binding transcription factor 4 (Oct4). Oct4 is essential to prevent ICM from diverting towards the TE lineage. Another important transcription factor, caudal type homeobox 2 (Cdx2), is specifically expressed in TE. It was demonstrated that Cdx2 is necessary to repress the expression of Oct4 in TE[15]. Moreover, Cdx2 null embryos exhibit high incidence of apoptosis[16].

Embryonic stem cells (ESCs), which are ICM-derived cell lines, despite of showing pluri-potency and self-renewal capacity, have ethical concerns restraint[16], because of their tumorigenic potential. On the other hand, mesenchymal stem cells (MSCs) are not subject of these ethical restraints, but show multipotency, that means a lower capacity to multiply and originate different cell lineages[17]. Surrogate systems to study early placent al development in the human species have been tried using human and mouse embryonic stem cells under bone morphogenetic protein (BMP) 2/4 stimulus to trophoblast differentiation and spontaneous formation of embryoid bodies[17,18]. MSCs are found in a lot of tissues, like the dentary tissue, adipocytes and bone marrow which culture provide inadequate cell numbers and have limitations like donor site morbidity and the need of aspiration to collect them, besides being a well-established culture. Attempts to overcome these problems were tried with alternative sources of MSCs and cells isolated from reproductive organs showed to be very useful. Thus, ovaries, uterus (endometrium) and specially the placenta[19-21], because of its discarded as medical waste after delivery, are potential sources of MSCs that can be used without ethical restrictions.

The p-SCs, which are TE-derived cell lines, gather some features from adult and embryo cells: possible differentiation to originate each of germative cells and absence of carcinogenicity[22-27]. In the First International Workshop on p-SCs terminologies standardization have been made[28] and according to the cell origin we should have amniotic epithelial or mesenchymal stromal cells, chorionic mesenchymal stromal or trophoblastic cells. In the present review it will be considered p-SCs in general, referring to any kind of them.

Cellular characterization

Immunophenotype characterization is the most common procedure used to distinguish different cell clusters, by means of surface marker expression, and some essays employed are immunolabeling[29] and flow cytometry[30]. The p-SCs show profiles merged with those found in embryonic and mesenchymal stem cells[26]. None of these three cell lineages (embryonic,
mesenchymal, and p-SC as well) express the clusters of differentiation (CD) 11b, 34, and 45. Regarding CD expression, p-SCs are positive for 29, 73 and 166, and negative for 11b, 31, 34, 45. In addition, they are positive for human leucocyte antigen (HLA) A, B, C and negative for HLA-DR, DP, DQ2,31,32.

The p-SCs fulfill the essential characteristics to categorize MSC[33] and are capable to originate ectodermal, endodermal, and mesodermal (adipocytes, osteocytes, and chondrocytes) lineages in vitro[29,31]. Moreover, p-SCs express surface cell markers only expressed by embryo-derived cells, such as Oct-4, SRY (sex determining region Y)-box 2 (Sox 2), Nanog, stage-specific embryonic antigen (SSEA)-1, SSEA-4, germ cell tumor marker (GCTM)-2, Tra-1-60, and Tra-1-80[22-24]. High levels of Oct-4, Sox 2 and Nanog were detected in p-SCs using q-PCR method[25]. Musashi-1, vimentin, polysialylated-neural cell adhesion molecule, and Nestin were observed in cells from amniotic membrane, unlike other MSCs, when evaluated by immunofluorescence technique[34].

**Cell culture**

Many different protocols for isolation of fetal membranes-derived stem cells are found in literature. For human beings and large animals, a separation of amniotic epithelial cells[21,35], amniotic mesenchymal cells[32] and chorionic mesenchymal cells[33] are possible, meanwhile for small animals, such as rodents, such characterization is not possible[31].

Fetal membranes are submitted to enzymatic disaggregation following different protocols, which differ among themselves particularly regarding enzymatic digestion and duration[7,8,23,31,35]. In every protocol, the cells are incubated with trypsin-EDTA or other enzymes, at 37 ℃, and then, are harvested through physical methods. Then cells are plated onto noncoated tissue culture dishes or flasks. Serum, like fetal bovine serum (FBS) ranging from 10% to 20%, must be added to the media. The most commonly used media are roswell park memorial institute (RPMI)-1640, Dulbecco’s modified eagle medium (DMEM), Minimum essential medium (EMEM), and DMEM/F12. Also, media should be enriched with nonessential amino acids, L-glutamine, β-mercaptoethanol, sodium pyruvate, and antibiotics. Cells are raised at controlled conditions of air atmosphere and temperature. For maintenance of the cell culture, p-SCs must have their medium (such as DMEM or RPMI) changed every other day.

To passage the cells, it should be used trypsin, and the cells are generally plated into T75 tissue culture flasks. Such culturing conditions are very similar with MSCs. On the other hand, ESCs need to be plated into T-flasks. Such culturing conditions are very similar with the cells are generally plated into T75 tissue culture flasks. Serum, like fetal bovine serum, should be enriched with nonessential amino acids. The most commonly used media (such as DMEM-F12 or RPMI-1640) must be changed every single day. To passage the cells, it should be used collagenase type IV or dispase, and the cells are generally plated into 6-well plates.

Finally, p-SCs may be cryopreserved using different media containing various concentrations of dimethyl sulfoxide, FBS and DMEM. Viability and cell numbers must be evaluated after thawing.

**CELL THERAPY USING P-SC**

**Basic considerations**

Three characteristics are important for the clinical application of p-SCs: the lack of ethical restrictions, pluripotency and their low immunogenicity[12]. An explanation for this is the low expression of MHC class II molecules, allowing these cells to be effectively employed in transplants[26].

Regarding to cellular therapy we have to consider the existence of cell banking due to the large amount of cells needed. Thus, those cells must have essential properties like to keep stable in subcultures, availability, great proliferation, freezing resistance, and high viability after thawing. The p-SCs fulfill most of these requirements. It has been mentioned that p-SCs even at subculture 30 showed high cellular division rates keeping a steady karyotype[25]. Different from p-SCs and ESCs, all other MSCs do not neither replicate nor exhibit high levels of cellular survival around subcultures 8 to 10.

Considering the freezing process, p-SCs require ordinary media (like MSCs, unlike ESCs), show intermediate resistance to low temperature (in between ESCs and MSCs) and show great viability after freezing-thawing (like ESCs, unlike MSCs).

Some of the p-SC uses in research are listed in Table 1, at the end of this section.

**Neurological diseases**

Human p-SC demonstrated neuroprotective effects after stroke in rats. Treatment of stroke with p-SCs (via intravenous administration) significantly increased vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and brain derived neurotrophic factor (BDNF) levels in the ischemic brain compared to controls (dextran vehicle or phosphate buffer saline) after middle cerebral arterial occlusion[36].

In Alzheimer’s disease, β-amyloid peptide is considered to be its root cause. Also, the neuroinflammatory process mediated by β-amyloid plaque-induced microglial cells and astrocytes contributes to Alzheimer’s disease pathogenesis. Thus, it was demonstrated that p-SCs transplanted into an Alzheimer’s disease mouse model modulated the properties of microglial cells toward a β-amyloid peptide plaque-reducing anti-inflammatory response. Moreover, p-SCs injected mice, compared to phosphate-buffered saline controls, had higher levels of β-amyloid degrading enzymes, reduced levels of proinflammatory cytokines, increased levels of anti-inflammatory cytokines (TGF-β and IL-10), slower progression of Alzheimer’s pathology, and
improved memory function[37].

Liver disease

Cell therapy for liver diseases has also been investigated. Among other sources of MSCs, p-SCs showed the greatest potential for hepatogenic differentiation and proliferation in vitro. The p-SCs, mainly those from chorionic plate, expressed higher levels of hepatocyte growth factor after differentiation[38].

In another study, chorionic-plate derived mesenchymal stem cells isolated from placenta could trigger autophagy to enhance regeneration in carbon tetrachloride injured rat liver model. After p-SC transplantation they observed reduction in apoptosis (caspase activity) and increasing levels of autophagy, survival and regeneration in liver cells[39].

Pancreatic disease

Human placenta-derived mesenchymal stem cells (p-SCs) have the potential to differentiate into insulin producing cells[40,41]. Also, p-SCs can form islet-like cell clusters which are capable of restoring normoglycemia when transplanted into streptozotocin-induced diabetic Balb/C mice[42].

Heart disease

In order to evaluate whether human amniotic membrane could limit posts ischemic cardiac injury, a fragment was applied onto the left ventricle of rats that had undergone ischemia through left anterior descending coronary artery ligation. The authors observed that the amniotic membrane fragment onto ischemic rat hearts could significantly reduce posts ischemic cardiac dysfunction once the rats showed higher values of left ventricle ejection fraction, fractional shortening and wall thickening on echocardiographic examinations[43].

In another study of myocardial infarction, pre-treated (with a hyaluronan mixed ester of butyric acid - HBR) p-SCs were intramyocardial injected in a pig model. Treated animals showed smaller infarct scar size and a significant improvement of the end-systolic wall thickening and circumferential shortening of the infarct border zone evaluated by magnetic resonance imaging[44].

Muscle disease

First-trimester chorionic-villi-derived cells were evaluated for potential therapeutic use in Duchenne muscular dystrophy, which is a X-linked disorder characterized by the absence of dystrophin at the sarcolemma of muscle fibers. The p-SCs efficiently differentiated into myotubes after myogenic induction, at which point Nanog and Sox2 were down-regulated, whereas MyoD, myogenin, desmin and dystrophin were up-regulated. The p-SCs could be efficiently directed to differentiate in vitro into skeletal muscle cells that express dystrophin as the last stage marker of myogenic differentiation[45].

The myogenic differentiation of fetal stem cells (p-SC, amniotic fluid stem cells, cord blood and whatton's jelly cells), were already reviewed and considerations about limitations and perspectives for therapeutically use were done[46].

Pulmonary disease

On a mouse model of bleomycin-induced lung fibrosis, cellular therapy using p-SCs promoted a decrease in neutrophil infiltration and a significant reduction in the severity of fibrosis, compared to control[47].

On a single centre, non-randomized, dose escalation phase 1b trial study, human patients with moderately to severe idiopathic pulmonary fibrosis received p-SCs via peripheral vein and they were evaluated follow up 6 mo. The variables analyzed were lung function (forced vital capacity and diffusing capacity for carbon monoxide), 6-min walk distance, gas exchange (assessed by resting PaO2), and lung fibrosis score (assessed by high-resolution computed tomography chest). Compared to baseline, at 6 mo all parameters were unchanged, with no evidence of worsening fibrosis and no side effects reported in the patients who had received p-SC injections[48].

Bone disease

Human fetal early chorionic stem cells (p-SCs) treatment was studied in a murine osteogenesis imperfecta model. It was demonstrated that intraperitoneal injection of p-SCs in osteogenesis imperfect neonates reduced fractures, increased bone ductility and bone volume, increased the numbers of hypertrophic chondrocytes, and upregulated endogenous genes involved in endochondral and intramembranous ossification[49].

Regenerative medicine using p-SC for bone disease (large lytic lesions) secondary to multiple myeloma was investigated. The authors founded p-SCs inhibitory effects on myeloma bone disease and tumor growth were dose-dependent and intrabone engraftment of p-SCs inhibited bone disease and tumor growth in mice severe combined immunodeficiency-rab model.
The p-SCs also promoted apoptosis in osteoclast precursors and inhibited their differentiation, indicating a promising therapeutic approach for myeloma osteolysis using cytotherapy.[50].

**CONCLUSION**

In summary, either the fetal or the maternal components of the placenta may be considered potential sources of stem cells once they share features from both cells of embryonic and mesenchymal origin. Phenotypically, these cells show common characteristics of embryo-derived and adult stem cells and do not express hematopoietic cell markers CD11b, CD 34 and CD 45. Different media to culture and stimuli to onward differentiation in p-SCs are under investigation and they have been used on research trials of cell therapy with promising results. Furthermore, it is important to get enough purity cells and to understand the mechanism of differentiation and engraftment of p-SC to improve cell-based therapy.

**REFERENCES**

1. Titomanlio L, Kavelaars A, Dalous J, Mani S, El Ghouzzi V, Heijnen C, Baud O, Gressens P. Stem cell therapy for neonatal brain injury: perspectives and challenges. *Ann Neurol* 2011; 70: 698-712 [PMID: 22162055 DOI: 10.1002/ana.22518]

2. Barboni B, Mango C, Valbonetti L, Marucchini G, Berardinelli P, Martelli A, Mattini A, Mauro A, Bedini R, Tarantini M, Pecchi R, Nardinocchi D, Zaccari Vl, Tezi S, Piattelli A, Mattoli M. Synthetic bone substitute engineered with amniotic epithelial cells enhances bone regeneration after maxillary sinus augmentation. *PLoS One* 2013; 8: e63256 [PMID: 23696804 DOI: 10.1371/journal.pone.0063256]

3. Ventura C, Cantoni S, Bianchi F, Lionetti V, Cavallini C, Scarlata I, Foroni L, Maioli M, Boni L, Alviano F, Fossati V, Bagnara GP, Pasquinelli G, Recchia FA, Perbellini A. Hyaluronan mixed esters of butyric and retinoic acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts. *J Biol Chem* 2007; 282: 14243-14252 [PMID: 17363374 DOI: 10.1074/jbc.M609350200]

4. Solt P. From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research. *Nat Rev Genet* 2006; 7: 319-327 [PMID: 16534514 DOI: 10.1038/nrg1727]

5. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. *Stem Cells* 2007; 25: 2739-2749 [PMID: 17656645 DOI: 10.1634/stemcells.2007-0197]

6. Wulf GG, Viereck V, Hemmerlein B, Haase D, Vehmeyer K, Pukrop T, Glass B, Emons G, Trümper L. Mesengenic progenitor cells derived from human placenta. *Tissue Eng* 2004; 10: 1136-1147 [PMID: 15363170]

7. Wolkbank S, van Griensven M, Grillari-Voglauer R, Peterbauer-Scherb A. Alternative sources of adult stem cells: human amniotic membrane. *Adv Biochem Eng Biotechnol* 2010; 123: 1-27 [PMID: 20237903]

8. Rus Ciucă D, Sorîjauo A, Suşman S, Pop VI, Mihu CM. Isolation and characterization of chorionic mesenchyal stem cells from the placenta. *Rom J Morphol Embryol* 2011; 52: 803-808 [PMID: 21892522]

9. Karlsson H, Erkers T, Nava S, Ruhm S, Westgren M, Rångdén O. Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. *Clin Exp Immunol* 2012; 167: 543-555 [PMID: 22288598 DOI: 10.1111/j.1365-2249.2011.04540.x]

10. Miao Z, Jin J, Chan L, Zhu J, Huang W, Zhao J, Qian H, Zhang X. Isolation of mesenchymal stem cells from human placenta: a new method for clinical application. *Stem Cells* 2009; 27: 1679-1684 [PMID: 19476308 DOI: 10.1002/stem.46].

**CHALLENGES**

A routine medical practice using stem cells is an exciting promise. And for this reason, any preclinical study regarding cell therapy must be considered cautiously. Besides the rapid evolution in differentiating stem cells into many different cell types, all protocols result in a mix cell preparations and how to get specialized cells in sufficient amount and purity is still a challenge. So, the really understanding of all the mechanisms from culturing stem cells to transplanting differentiated ones into a patient is of great importance in order to let the dream comes true.
comparison with human bone marrow mesenchymal stem cells. *Cell Biol Int* 2006; 30: 681-687 [PMID: 16807487]

11 Appr R, Murphy SP, Fernando R, Gardner L, Ahad T, Moffett A. Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single colour beads to characterize allelic type specificity of anti-HLA antibodies. *Immunology* 2009; 127: 26-39 [PMID: 19368562 DOI: 10.1111/j.1365-2567.2008.03019.x]

12 Parolini O, Caruso M. Review: Preclinical studies on placenta-derived cells and amniotic membrane: an update. *Placenta* 2011; 32 Suppl 2: S186-S195 [PMID: 21251712 DOI: 10.1016/j.placenta.2010.12.016]

13 Bailo M, Soncin M, Vertu E, Signoroni PB, Sanzonne S, Lombardi G, Arienti D, Calamani F, Zatti D, Paul P, Albertini A, Zorzi F, Cavagnini A, Candotti F, Wenger GS, Parolini O. Engraftment potential of human amnion and chorion cells derived from term placenta. *Placenta* 2004; 25: 1439-1448 [PMID: 15599307 DOI: 10.1016/S0143-7254(03)00193-9]

14 Marikawa Y, Alarcón VB. Establishment of trophoderm and inner cell mass lineages in the mouse embryo. *Mol Reprod Dev* 2006; 76: 1019-1032 [PMID: 17437991 DOI: 10.1002/mrd.20157]

15 Strumpf D, Mao CA, Yamanaka Y, Ralston A, Chawangsaksophon K, Beck F, Rossant J. Cdx2 is required for correct cell fate specification and differentiation of trophoderm in the mouse blastocyst. *Development* 2005; 132: 2093-2102 [PMID: 15788452]

16 Rossant J. Developmental biology: A mouse is not a cow. *Nature* 2011; 471: 457-458 [PMID: 21430771 DOI: 10.1038/471457a]

17 Golos TG, Giakoamopoulos M, Germaini-Naini B. Review: Trophoblast differentiation from human embryonic stem cells. *Placenta* 2013; 34 Suppl: S56-S61 [PMID: 23261342 DOI: 10.1016/placenta.2012.11.019]

18 Hayashi Y, Furue MK, Tanaka S, Hirose M, Wakisaka N, Danno H, Ohnuma K, Oeda S, Aihara Y, Shiotani K, Ogura A, Ishiura S, Asashima M. BMP4 induction of trophoblast from mouse embryonic stem cells in defined culture conditions on laminin. *In Vitro Cell Dev Biol Anim* 2010; 46: 416-430 [PMID: 20337990 DOI: 10.1007/s11626-009-9266-6]

19 Mohr S, Portmann-Lanz CB, Schoberlein A, Sager R, Surbek DV. Generation of an ovarian graft from human placenta and placenta-derived mesenchymal stem cells. *Reprod Sci* 2010; 17: 1006-1015 [PMID: 20940246 DOI: 10.1177/1933719109377471]

20 Shin KS, Lee HH, Jung J, Cha DH, Kim GJ. Culture and in vitro hepatogenic differentiation of placenta-derived stem cells, using placental extract as an alternative to serum. *Cell Prolif* 2010; 43: 223-234 [PMID: 2087550 DOI: 10.1111/j.1365-2184.2010.00693.x]

21 Vidane AS, Zoetmeier-HD, Oliveira BM, Giakoumopoulos M, Oliveira MS. Generation of an osteogenic graft from human placenta and placenta-derived stem cells and amniotic membrane: an update. *J. Reprod Immunol.* 2011; 93 Suppl: S56-S61 [PMID: 23261342 DOI: 10.1016/j.repi.2011.03.029]

22 Fujimoto KL, Miki T, Liu LJ, Hashizume R, Strom SC, Wagner WR, Keller BB, Tobita K. Naive rat amnion-derived cell lineage commitment. Reprod Sci 2013; 20: 1137-1143 [PMID: 23420825 DOI: 10.1177/1933719113477484]

23 Manuelpillai U, Tchongue J, Lourensz D, Vaghjiani V, Samuels CS, Liu A, Williams ED, Sievert W. Human amnion epithelial cells reduce hepatic fibrosis in immunocompetent CCI-treated mice. *Cell Transplant* 2010; 19: 1157-1168 [PMID: 20447339 DOI: 10.3727/096368910X504496]

24 Moodley J, Ibanchez S, Samuel C, Vaghjiani V, Atienza D, Williams ED, Jenkin G, Wallace E, Trounson A, Manuelpillai U. Human amnion epithelial cell transplantation abrogates lung fibrosis and augments repair. *Am J Resp Crit Care Med* 2010; 182: 643-651 [PMID: 20522792 DOI: 10.1164/rcrm.20100101.001OC]

25 Sabapathy V, Ravi S, Srivistava V, Srivastava A, Kumar S. Long-term cultured human term placenta-derived mesenchymal stem cells of maternal origin displays plasticity. *Stem Cells Int* 2012; 2012: 174328 [PMID: 22550499 DOI: 10.1155/2012/174328]
hepatic regeneration in CC14 -injured rat liver model via increased autophagic mechanism. *Stem Cells* 2013; 31: 1584-1596 [PMID: 23592412 DOI: 10.1002/stem.1396]

40 Chang CM, Kao CL, Chang YL, Yang MJ, Chen YC, Sung BL, Tsai TH, Chao KC, Chiou SH, Ku HH. Placenta-derived multipotent stem cells induced to differentiate into insulin-positive cells. *Biochem Biophys Res Commun* 2007; 357: 414-420 [PMID: 17433254 DOI: 10.1016/j.bbrc.2007.03.157]

41 Sun NZ, Ji HS. In vitro differentiation of human placenta-derived adherent cells into insulin-producing cells. *J Int Med Res* 2010; 37: 400-406 [PMID: 19383234 DOI: 10.1177/03000605093700215]

42 Kadam S, Muthyala S, Nair P, Bhonde R. Human placenta-derived mesenchymal stem cells and islet-like cell clusters generated from these cells as a novel source for stem cell therapy in diabetes. *Rev Diabet Stud* 2010; 7: 168-182 [PMID: 21060975 DOI: 10.1900/RDS.2010.7.168]

43 Cargnoni A, Di Marcello M, Campagnol M, Nassuato C, Albertini A, Parolini O. Amniotic membrane patching promotes ischemic rat heart repair. *Cell Transplant* 2009; 18: 1147-1159 [PMID: 19650976 DOI: 10.1080/09636990903127512]

44 Stimoniuc A, Campan M, Lionetti V, Marinelli M, Aquaro GD, Cavallini C, Valente S, Di Silvestre D, Cantoni S, Bernini F, Simi C, Pardini S, Mauri P, Neglia D, Ventura C, Pasquinelli G, Reechia FA. Placental stem cells pre-treated with a hyaluronan mixed ester of butyric and retinoic acid to cure infarcted pig hearts: a multimodal study. *Cardiovasc Res* 2011; 90: 546-556 [PMID: 21257613 DOI: 10.1093/cvr/cvr018]

45 Arakawa R, Aoki R, Arakawa M, Saito K. Human first-trimester chorionic villi have a myogenic potential. *Cell Tissue Res* 2012; 348: 189-197 [PMID: 22370594 DOI: 10.1007/s00441-012-1340-9]

46 Pozzobon M, Franzin C, Piccoli M, De Coppi P. Fetal stem cells and skeletal muscle regeneration: a therapeutic approach. *Front Aging Neurosci* 2014; 6: 222 [PMID: 25221507 DOI: 10.3389/ fnagi.2014.00222]

47 Cargnoni A, Gibelli L, Tosini A, Signoroni PB, Nassuato C, Arienti D, Lombardi G, Albertini A, Wengler GS, Parolini O. Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. *Cell Transplant* 2009; 18: 405-422 [PMID: 19622228 DOI: 10.3727/096368909788809857]

48 Chambers DC, Enever D, Ilic N, Sparks L, Whitelaw K, Ayres J, Yerkovich ST, Khalil D, Atkinson KM, Hopkins PM. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. *Respirology* 2014; 19: 1013-1018 [PMID: 25039426 DOI: 10.1111/resp.12343]

49 Jones GN, Moschidou D, Abdulrazzakz K, Kalirai BS, Vanleeene M, Osatis S, Shlefeline SJ, Horwood NJ, Marenzana M, De Coppi P, Bassett JH, Williams GR, Fisk NM, Guillot PV. Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta. *Stem Cells Dev* 2014; 23: 262-276 [PMID: 24028330 DOI: 10.1089/scd.2013.0132]

50 Li X, Ling W, Pennisi A, Wang Y, Khan S, Heidarman M, Pal A, Zhang X, He S, Zeitlin A, Abbot S, Faleck H, Hariri R, Shaughnassy JD, van Rhee F, Nair B, Barlogie B, Epstein J, Yacobcy S. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. *Stem Cells* 2011; 29: 263-273 [PMID: 21732848 DOI: 10.1002/stem.1010]

51 Jin J, Wang J, Huang J, Huang F, Fu J, Yang X, Miao Z. Transplantation of human placenta-derived mesenchymal stem cells in a silk fibron/hydroxyapatite scaffold improves bone repair in rabbits. *J Biosci Bioeng* 2014; 118: 593-598 [PMID: 24894683 DOI: 10.1016/j.jbiosc.2014.05.001]

52 Wang Y, Guo G, Chen H, Gao X, Fan R, Zhang D, Zhou L. Preparation and characterization of poly(lactide-co(poly-ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) hybrid fibers for potential application in bone tissue engineering. *Int J Nanomedicine* 2014; 9: 1991-2003 [PMID: 24790439 DOI: 10.2147/IJN.S55318]

53 Lisi A, Briganti E, Ledda M, Losi P, Grimaldi S, Marchese R, Soldani G. A combined synthetic-fibrin scaffold supports growth and cardiomyogenic commitment of human placental derived stem cells. *PLoS One* 2012; 7: e34284 [PMID: 22509287 DOI: 10.1371/journal.pone.0034284]

54 Numata R, Okumura N, Nakahara M, Ueno M, Kinoshita S, Kanematsu D, Kanemura Y, Sasai Y, Koizumi N. Cultivation of corneal endothelial cells on a pericellular matrix prepared from human decidua-derived mesenchymal cells. *PLoS One* 2014; 9: e88169 [PMID: 25405413 DOI: 10.1371/journal.pone.0088169]
